Data as of Dec 12
| +0.01 / +0.06%|
Insmed, Inc. is a development stage biopharmaceutical company with expertise in proprietary, advanced liposomal technology designed specifically for inhalation lung delivery. It develops inhaled treatments for serious lung infections. The proprietary liposomal technology is designed specifically for delivery of pharmaceuticals to the lung, and it provides for potential improvements to the conventional inhalation methods of delivering drug to the pulmonary system. The company focuses on markets with high unmet medical needs, orphan markets, which present a significant opportunity. Its main product is IPLEX, which is a complex of recombinant human IGF-1 and its binding protein IGFBP-3, is being studied as a treatment for several serious medical conditions. Insmed was founded on November 29, 1999 and is headquartered in Monmouth Junction, NJ.
|William H. Lewis||President, Chief Executive Officer & Director|
|Andrew T. Drechsler||Chief Financial & Accounting Officer|
|Renu Gupta||Chief Medical Officer & Executive VP-Development|
|Walter R. Perkins||Chief Technology Officer|
|Andrea Holtzman Drucker||Secretary, Senior Vice President & General Counsel|